替沙基奥仑赛治疗复发/难治性髓外急性淋巴细胞白血病的结局:儿童真实世界CAR联盟报告
该回顾性研究基于儿童真实世界CAR联盟(PRWCC)15家美国机构184例输注患者,比较替沙基奥仑赛治疗髓外(EM)病变与仅骨髓(BM)病变患者的结局。55例EM患者中,CNS3组40例完全缓解率88%,非CNS EM组15例为66%;CNS组24个月OS与非CNS EM或BM-only组相当(P=0.41),12个月RFS无差异(P=0.92),毒性未增加(P=0.3)。
要点
- CNS3患者完全缓解率88%(35/40),非CNS EM患者为66%(10/15)。
- CNS组24个月OS与非CNS EM或BM-only组相当(P=0.41)。
- CNS、非CNS EM与BM-only组12个月RFS无差异(P=0.92)。
核心结论
- 复发/难治性髓外病变可经替沙基奥仑赛有效治疗,毒性、复发和生存率与仅骨髓病变患者相当,孤立CNS复发结局令人鼓舞。
研究设计与样本
- 回顾性研究,数据来自儿童真实世界CAR联盟(PRWCC),纳入15家美国机构184例输注患者,其中55例CAR治疗前存在髓外病变(CNS3 40例,非CNS EM 15例)。
主要发现
- CNS疾病组完全缓解率88%(35/40),非CNS EM组66%(10/15)。
- CNS组(伴或不伴BM受累)24个月OS与非CNS EM或BM-only组相当(P=0.41)。
- CNS、非CNS EM与BM-only组12个月RFS无差异(P=0.92)。
- CNS或非CNS EM疾病未增加毒性(P=0.3)。
- 输注时活动性CNS疾病不影响结局;孤立CNS疾病较CNS合并BM有OS改善趋势(P=0.12)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cells have transformed the therapeutic options for relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia. Data for CAR therapy in extramedullary (EM) involvement are limited. Retrospective data were abstracted from the Pediatric Real World CAR Consortium (PRWCC) of 184 infused patients from 15 US institutions. Response (complete response) rate, overall survival (OS), relapse-free survival (RFS), and duration of B-cell aplasia (BCA) in patients referred for tisagenlecleucel with EM disease (both central nervous system (CNS)3 and non-CNS EM) were compared with bone marrow (BM) only. Patients with CNS disease were further stratified for comparison. Outcomes are reported on 55 patients with EM disease before CAR therapy (CNS3, n = 40; non-CNS EM, n = 15). The median age at infusion in the CNS cohort was 10 years (range, <1-25 years), and in the non-CNS EM cohort it was 13 years (range, 2-26 years). In patients with CNS disease, 88% (35 of 40) achieved a complete response vs only 66% (10 of 15) with non-CNS EM disease. Patients with CNS disease (both with and without BM involvement) had 24-month OS outcomes comparable to those of non-CNS EM or BM only (P = .41). There was no difference in 12-month RFS between CNS, non-CNS EM, or BM-only patients (P = .92). No increased toxicity was seen with CNS or non-CNS EM disease (P = .3). Active CNS disease at time of infusion did not affect outcomes. Isolated CNS disease trended toward improved OS compared with combined CNS and BM (P = .12). R/R EM disease can be effectively treated with tisagenlecleucel; toxicity, relapse, and survival rates are comparable to those of patients with BM-only disease. Outcomes for isolated CNS relapse are encouraging.
引用
- Fabrizio VA, Phillips CL, Lane A, et al. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report. Blood Adv. 2022. PMID: 34794180. doi:10.1182/bloodadvances.2021005564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。